Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7658216 | 0.88 | EGFR (0.31) | — | |
| SCHEMBL7602009 | 0.85 | — | — | |
| SCHEMBL7594681 | 0.85 | HRH4 (0.36) | TRPA1 | |
| SCHEMBL7595081 | 0.83 | GAA (0.32) | — | |
| SCHEMBL7601120 | 0.82 | COMT (0.31) | — | |
| SCHEMBL29435262 | 0.78 | GAA (0.32) | — | |
| SCHEMBL19641780 | 0.78 | GAA (0.32) | — | |
| SCHEMBL7660906 | 0.78 | KHK (0.40) | — | |
| SCHEMBL10577873 | 0.78 | PPOX (0.35) | — | |
| SCHEMBL7595408 | 0.77 | GAA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1255724-A1 | SUBSTITUTED NORBORNYLAMINO DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR A DIAGNOSTIC REAGENT AND MEDICAMENTS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-11-13 | — | — | EP | disclosed |
| US-20020156285-A1 | Novel herbicides | KUNZ WALTER (CH) | 2002-10-24 | — | — | US | disclosed |
| US-6369002-B1 | HETERO IS PYRIMIDINE OR PYRIDAZINE; 1-(3-FLUORO-5-CHLORO PYRIDIN-2-YL)-3-METHYL-4-TRIFLUOROMETHYLPYRIMIDIN-2,6-DIONE | SYNGENTA CROP PROPERTIES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2001044164-A1 | SUBSTITUTED NORBORNYLAMINO DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR A DIAGNOSTIC REAGENT AND MEDICAMENTS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-21 | — | — | WO | disclosed |
| EP-1076656-A2 | N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | Novartis AG (CH) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055693-A2 | N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156285-A1 | Novel herbicides | DDT, CBR1, CBR3 | P2RX7 3623/4885TRPA1 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.